- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
SOLX receives clearance for glaucoma implant use in Canada
SOLX has received clearance from Health Canada for the use of its 24-karat gold implant (SOLX Gold Shunt) during glaucoma surgery.
Waltham MA
-SOLX has received clearance from Health Canada for the use of its 24-karat gold implant (SOLX Gold Shunt) during glaucoma surgery.
The shunt is biocompatible, 99.95% pure gold, and is designed to provide a pathway for the flow of aqueous humor from the anterior chamber of the eye to the suprachoroidal space. It preserves precious eye surface and the ability to perform future surgical interventions without a bleb, according to the company.
In a prospective, open-label study of the implant with 12 months of follow-up, IOP was reduced 45.6% from best medicated baseline in patients in whom maximum medical therapy and at least one prior surgical intervention had failed, according to the company.
The company’s family of shunt devices joins its laser for trabeculoplasty (SOLX 790) in products that have been cleared for sale in Canada.
